Tag Archives: Boehringer Ingelheim

Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases

Beirut, Lebanon – 3 July 2017- Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, held an event to launch their latest innovative type 2 diabetes treatment in Lebanon. The event brought together leading experts in internal medicine and primary care physicians to highlight the latest innovative, convenient medical solutions and findings in cardiovascular implications

Christoph Raab

Boehringer Ingelheim Middle East and North Africa (MENA) achieved a sales growth of 16% in 2016

Net sales rise to some 15.9 billion euros (currency-adjusted: +7.3 per cent; in euro terms: +7.1 per cent) Operating income improves to around 2.9 billion euros Corporate strategy successfully implemented In 2016, Boehringer Ingelheim Middle East and North Africa region (MENA) achieved overall 16% growth, 15 Product launches and 20 market authorization. Strongest Countries performance

Karim  Bjoern

Boehringer Ingelheim has a successful 2015 financial year

Boehringer Ingelheim Middle East and North Africa Region achieved a sales growth of 26% and 4% in Lebanon   Net sales globally to rise to 14.8 billion euros (currency-adjusted: +4.1 per cent; +11.1 per cent in euro terms) Operating income improves markedly to 2.3 billion euros Key strategic course set for future sustainable business development In 2015, Boehringer